Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32393593.
- Also identified by DOI 10.3949/ccjm.87a.ccc015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In COVID-19, respiratory infection with SARS-CoV-2 plus another virus (viral co-infection) or with SARS-CoV-2 plus a bacterial pathogen (combined viral and bacterial pneumonia) has been described. Secondary bacterial pneumonia can follow the initial phase of viral respiratory infection or occur during the recovery phase. No obvious pattern or guidelines exist for viral co-infection, combined viral and bacterial pneumonia, or secondary bacterial pneumonia in COVID-19. Based on existing clinical data and experience with similar viruses such as influenza and SARS-CoV, the management approach in COVID-19 should, ideally, take into consideration the overall presentation and the trajectory of illness.
Medical subject headings
- Anti-Bacterial Agents
- Coinfection
- Coronavirus Infections
- Pandemics
- Patient Care Management
- Pneumonia, Bacterial
- Pneumonia, Viral
- Virus Diseases